(Q46910751)

English

Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome

scientific article published in March 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16435387

Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome (English)

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16435387

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

1

object named as

Hagop Kantarjian

1 reference

Europe PubMed Central

26 December 2017

4

object named as

Susan O'Brien

1 reference

Europe PubMed Central

26 December 2017

5

object named as

Francis Giles

1 reference

Europe PubMed Central

26 December 2017

6

object named as

Sherry Pierce

1 reference

Europe PubMed Central

26 December 2017

Jorge Eduardo Cortes

3

object named as

Jorge Cortes

1 reference

Europe PubMed Central

26 December 2017

Michael J. Keating

9

object named as

Michael Keating

1 reference

Europe PubMed Central

26 December 2017

William Plunkett

8

object named as

William Plunkett

1 reference

Europe PubMed Central

26 December 2017

10

object named as

Elihu Estey

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16435387

7

object named as

Jianqin Shan

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16435387

author name string

Miloslav Beran

2

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16435387

language of work or name

0 references

publication date

1 March 2006

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16435387

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16435387

106

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16435387

5

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16435387

1099-1109

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16435387

Proposals for the classification of the myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

21 January 2018

Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

21 January 2018

Novel therapies for myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

The fundamental role of epigenetic events in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

Methylation status of the p15INK4B gene in hematopoietic progenitors and peripheral blood cells in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunosuppressive therapy for hypoplastic myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiangiogenic therapy in leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of the beta 4 integrin subunit induces monocytic differentiation of 32D/v-Abl cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of lenalidomide in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

Common lymphoid progenitors rapidly engraft and protect against lethal murine cytomegalovirus infection after hematopoietic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long-term survivors and outcome of partial responders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative expressed sequence hybridization studies of hairy cell leukemia show uniform expression profile and imprint of spleen signature

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21699

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.21699

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16435387

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16435387

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46910751&oldid=2137602244"